Stockscreener 앱 받기
2.63
2.59%
-0.07
전일 마감가:
$2.70
열려 있는:
$2.73
하루 거래량:
318.43K
Relative Volume:
0.72
시가총액:
$189.96M
수익:
-
순이익/손실:
$-113.28M
주가수익비율:
-1.4173
EPS:
-1.8557
순현금흐름:
$-105.55M
1주 성능:
-4.01%
1개월 성능:
+17.41%
6개월 성능:
+45.30%
1년 성능:
+102.31%
1일 변동 폭
$2.5399
$2.73
1주일 범위
$2.47
$2.78
52주 변동 폭
$1.1901
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
명칭
Acumen Pharmaceuticals Inc
전화
617-344-4190
주소
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.63 | 189.96M | 0 | -113.28M | -105.55M | -1.8557 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-07-26 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-20 | 재개 | BofA Securities | Buy |
| 2023-05-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-07-15 | 개시 | BTIG Research | Buy |
| 2022-06-30 | 개시 | H.C. Wainwright | Buy |
| 2022-01-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-07-26 | 개시 | BofA Securities | Neutral |
| 2021-07-26 | 개시 | Credit Suisse | Outperform |
| 2021-07-26 | 개시 | Stifel | Buy |
| 2021-07-26 | 개시 | UBS | Buy |
모두보기
Acumen Pharmaceuticals Inc 주식(ABOS)의 최신 뉴스
Acumen Pharmaceuticals (ABOS) Holds at Support Amid Modest Decline – Key Levels in FocusATR Trailing Stop - dars.gov.et
Acumen Pharmaceuticals and Unlearn Collaborate to Explore Analyses of Alzheimer's Disease Clinical Programs - ACCESS Newswire
Acumen Pharmaceuticals (ABOS) Dips 2.43% as Stock Approaches Key Support LevelSweep Order Flow - dars.gov.et
Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 - The Manila Times
Acumen to show brain-delivery data and patient insights at AAIC 2026 - Stock Titan
Number of shareholders of Acumen Pharmaceuticals, Inc. – NASDAQ:ABOS - TradingView
Acumen Pharmaceuticals, Inc. commits to advancing targeted therapies for Alzheimer care - Traders Union
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Index - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS: ABOS) added to Russell 2000 Value Benchmark - marketscreener.com
Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) added to Russell Small Cap Comp Value Benchmark - marketscreener.com
ABOS Q1 2026 Earnings: EPS Beat Strong as Acumen Advances Alzheimer’s PipelineRevenue Recognition Risk - dars.gov.et
Acumen Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ABOS) - TradingView
ABOS Forecast — Price Target — Prediction for 2027 - TradingView
Acumen Pharmaceuticals Inc (ABOS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Acumen Pharmaceuticals (ABOS) Holds Steady Near $2.26 as Biotech Sector Watches for Next MoveBearish Pattern Stocks - dars.gov.et
Acumen Pharmaceuticals Inc (ABOS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform - BioSpace
Acumen Pharmaceuticals Inc (ABOS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Acumen Pharmaceuticals Insider Makes Eye-Catching Stock Move - TipRanks
Acumen Pharmaceuticals director Porter sells $75,239 in stock - Investing.com UK
Acumen Pharmaceuticals director Porter sells $75,239 in stock By Investing.com - Investing.com Australia
Acumen Pharmaceuticals Inc (ABOS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acumen Pharmaceuticals Inc - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acumen Pharmaceuticals (ABOS) director sells 32,300 shares after exercising options - Stock Titan
Acumen exercises option for JCR brain technology - grafa.com
Acumen Pharmaceuticals Inc (ABOS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acumen Pharmaceuticals Inc (ABOS) Institutional Confidence - TradingKey
Director to sell 13,040 shares (NASDAQ: ABOS) in stock option exercise - Stock Titan
Acumen selects development candidates for Alzheimer’s disease - BioWorld News
Acumen nominates two Alzheimer’s candidates for development - Investing.com UK
Acumen nominates two Alzheimer’s candidates for development By Investing.com - Investing.com South Africa
Acumen Nominates 2 Therapies to Treat Alzheimer’s Disease - Yahoo Finance
ABOS (NASDAQ: ABOS) Form 144 shows proposed sale of 12,800 shares - Stock Titan
Acumen Pharmaceuticals, Inc. advances two new Enhanced Brain Delivery candidates for Alzheimer treatment - Traders Union
Acumen Advances Enhanced Brain Delivery Alzheimer’s Drug Candidates - TipRanks
Acumen Pharmaceuticals nominates two EBD candidates, targets mid-2027 IND with 14-40x brain penetration in NHPs - TradingView
Acumen Pharmaceuticals Nominates Two Development Candidates in Enhanced Brain Delivery Program for Alzheimer's Disease Treatment - Quiver Quantitative
Acumen (NASDAQ: ABOS) advances two EBD Alzheimer’s drug candidates - Stock Titan
Two new antibody designs aim for higher brain delivery in Alzheimer’s - Stock Titan
[144] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Acumen Pharmaceuticals Slides 1.27% as Alzheimer’s Stock Tests Key Support at $2.22Bollinger Squeeze - dars.gov.et
Bank of America Securities Keeps Their Buy Rating on Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Acumen Pharmaceuticals Q1 earnings call highlights - MSN
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Acumen Pharmaceuticals director sells $14,272 in company stock By Investing.com - Investing.com Nigeria
Acumen Pharmaceuticals director sells $14,272 in company stock - Investing.com
Insider Sell: Nathan Fountain Sells 6,400 Shares of Acumen Pharm - GuruFocus
Acumen Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Fountain Nathan B - Moomoo
Director Nathan Fountain sells 6,400 Acumen (ABOS) shares at ~$2.23 - Stock Titan
Acumen Pharmaceuticals Inc (ABOS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acumen Pharmaceuticals Inc 주식 (ABOS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Porter Derrell | Director |
Jun 15 '26 |
Option Exercise |
1.07 |
6,460 |
6,912 |
54,760 |
| Porter Derrell | Director |
Jun 17 '26 |
Sale |
2.33 |
13,040 |
30,318 |
35,500 |
| Porter Derrell | Director |
Jun 16 '26 |
Sale |
2.33 |
12,800 |
29,773 |
35,500 |
| Porter Derrell | Director |
Jun 15 '26 |
Sale |
2.35 |
6,460 |
15,149 |
48,300 |
2.64%
자본화:
|
볼륨(24시간):